Mitapivat and Ganaxolone: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Ganaxolone
Mitapivat
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced ganaxolone exposure and reduced efficacy of ganaxolone
Interaction Deep Dive
Avoid coadministration of ganaxolone with a strong or moderate CYP3A4 inducer because reduced ganaxolone exposure may lead to reduced efficacy. Coadministration of ganaxolone (CYP3A4 substrate) with rifAMPin (strong CYP3A4 inducer) reduced ganaxolone Cmax by 57% and AUC by 68%. If concurrent use is unavoidable, consider an increase in ganaxolone dosage, not to exceed the maximum daily dosage1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of ganaxolone
Literature reports
1 report — tap to read
a) Coadministration of ganaxolone with rifAMPin (CYP3A4 inducer) reduced ganaxolone Cmax by 57% and AUC by 68% 1.
Common questions
Can I take Mitapivat and Ganaxolone together?
Reduced ganaxolone exposure and reduced efficacy of ganaxolone Always confirm with your pharmacist or prescriber before making any change.
How serious is the Mitapivat and Ganaxolone interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Mitapivat or Ganaxolone need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ZTALMY® oral suspension, ganaxolone oral suspension. Marinus Pharmaceuticals Inc (per FDA), Radnor, PA, 2025. DailyMed
Keep reading about Ganaxolone
Keep reading about Mitapivat
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist